LYRA Projected Dividend Yield
Lyra Therapeutics Inc ( NASDAQ : LYRA )Lyra Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of therapies for the treatment of patients with chronic rhinosinusitis (CRS). Co.'s technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Co.'s product candidates, LYR-210, which is designed to treat CRS patients both with and without nasal polyps who have failed previous medical management and have not undergone endoscopic sinus surgery; and LYR-220, which is also designed to utilize mometasone furoate, and employs a larger matrix designed for patients whose nasal cavity is enlarged due to sinus surgery. 20 YEAR PERFORMANCE RESULTS |
LYRA Dividend History Detail LYRA Dividend News LYRA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |